eligibility_summary
Eligible: histologically confirmed, untreated advanced NSCLC (stage IIIb/IIIc not candidates for definitive chemoradiation/radiation/surgery, or stage IV), known PD-L1, ≥1 measurable lesion (RECIST 1.1), ECOG 0–1. Exclude: active autoimmune disease needing steroids/immunosuppressors in past 2 yrs, severe drug/mAb hypersensitivity, active CNS mets/meningitis, EGFR/ALK alterations, or other targetable drivers (BRAF V600, KRAS G12C, MET ex14, NTRK, RET, ROS1). Other criteria apply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drugs/interventions: • Ociperlimab (WCD118/BGB-A1217): humanized anti-TIGIT monoclonal antibody (IgG1) given IV, combined with tislelizumab and chemotherapy. • Tislelizumab (VDT482/BGB-A317): anti-PD-1 monoclonal antibody (IgG4). • Comparator includes pembrolizumab (anti-PD-1 mAb) plus the same chemotherapy, or tislelizumab plus chemo with placebo. • Chemotherapy: carboplatin/cisplatin (platinum DNA cross-linkers), pemetrexed (antifolate, TS/DHFR inhibition), paclitaxel or nab-paclitaxel (microtubule stabilizers). Mechanisms/targets: • Immune checkpoints: TIGIT–CD155 axis (ociperlimab) on T cells and NK cells, PD-1–PD-L1/PD-L2 axis (tislelizumab/pembrolizumab) on T cells to reverse exhaustion, ociperlimab’s IgG1 Fc can engage Fcγ receptors. • Cytotoxic pathways: DNA damage/repair (platinum), folate/thymidylate synthesis (pemetrexed), and mitotic spindle/microtubules (taxanes).